DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1752 patients with CD33-positive acute myeloid leukemia in first
recurrence. Cancer, 2005, 104:1442–1452.
List AF. Lenalidomide—The phoenix rises. N Engl J Med, 2007,
357:2183–2186.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med, 2008, 359:378–390.
Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8
(rituximab) anti-CD20 monoclonal antibody therapy in
patients with relapsed low-grade non-Hodgkin’s lymphoma.
Blood, 1997, 90:2188–2195.
Maloney DG, Smith B, Rose A. Rituximab. Mechanism of action
and resistance. Semin Oncol, 2002, 29:2–9.
McDermott DF. Immunotherapy of metastatic renal cell carcinoma.
Cancer, 2009, 115:2298–2305.
Medina PJ, Goodin S. Lapatinib: A dual inhibitor of human epidermal
growth factor receptor tyrosine kinases. Clin Ther,
2008, 30:1426–1447.
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab
versus paclitaxel alone for metastatic breast cancer. N Engl J
Med, 2007, 357:2666–2676.
Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling
induced by immunomodulatory thalidomide analogs in human
multiple myeloma cells: Therapeutic implications. Blood,
2002a, 99:4525–4530.
Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of
nuclear factor-κB blockade in multiple myeloma: Therapeutic
applications. Blood, 2002b, 99:4079–4086.
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine
compared with gemcitabine alone in patients with
advanced pancreatic cancer: A phase III trial of the National
Cancer Institute of Canada Clinical Trials Group. J Clin Oncol,
2007, 25:1960–1966.
Morel F, Bris MJ, Herry A, et al. Double minutes containing
amplified bcr-abl fusion gene in a case of chronic myeloid
leukemia treated by imatinib. Eur J Haematol, 2003, 70:
235–239.
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus
in advanced renal cell carcinoma: A double-blind, randomised,
placebo-controlled phase III trial. Lancet, 2008, 372:449–456.
Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy
against advanced renal cell carcinoma. J Urol, 2007, 178:
1883–1887.
Moy B, Goss PE. Lapatinib-associated toxicity and practical management
recommendations. Oncologist, 2007, 12:756–765.
Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT.
Incidence and prophylaxis of venous thromboembolic events
in multiple myeloma patients receiving immunomodulatory
therapy. Thromb Res, 2008, 123:679.
Nahta R, Esteva FJ. HER-2-targeted therapy: Lessons learned
and future directions. Clin Cancer Res, 2003, 9:5078–5084.
Negro-Vilar A, Dziewanowska Z, Groves ES, et al. Efficacy and
safety of denileukin diftitox (dd) in a phase III, double-blind,
placebo-controlled study of CD25+ patients with cutaneous
T-cell lymphoma (CTCL). J Clin Oncol, 2007, 25:8026.
O’Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib
mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin,
a cyto-chrome p450 3A4 substrate, in patients with
chronic myeloid leukemia. Br J Cancer, 2003, 89:1855–1859.
O’Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacodynamic
study of the oral mammalian target of rapamycin
SECTION VIII
CHEMOTHERAPY OF NEOPLASTIC DISEASES
inhibitor everolimus in patients with advanced solid tumors.
J Clin Oncol, 2008, 26:1588–1595.
O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of
bcr-abl inhibitors AMN107 and BMS-354825 against clinically
relevant imatinib-resistant abl kinase domain mutants.
Cancer Res, 2005, 65:4500–4505.
Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two
dose levels of denileukin diftitox for the treatment of cutaneous
T-cell lymphoma. J Clin Oncol, 2001, 19:376–388.
Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase
III study of pegylated liposomal doxorubicin plus bortezomib
compared with bortezomib alone in relapsed or refractory multiple
myeloma: Combination therapy improves time to progression.
J Clin Oncol, 2007, 25:3892.
Papandreou CN, Daliani DD, Nix D, et al. Phase 1 trial of the
proteasome inhibitor bortezomib in patients with advanced
solid tumors with observations in androgen-independent
prostate cancer. J Clin Oncol, 2004, 22:2108–2121.
Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics
of imatinib in a phase 1 trial with chronic
myeloid leukemia patients. J Clin Oncol, 2004, 22:935–942.
Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al.
Hearing improvement after bevacizumab in patients with neurofibromatosis
type 2. N Engl J Med, 2009, 361:358–367.
Richardson P, Jagannath S, Raje N, et al. Lenalidomide, bortezomib,
and dexamethasone (Rev/Vel/Dex) in patients with
relapsed or relapsed/refractory multiple myeloma (MM):
Preliminary results of a phase II study. Blood, 2007, 110:797A.
Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for
patients with relapsed multiple myeloma after high-dose
chemotherapy and stem cell transplantation: Results of an
open-label multicenter phase 2 study of efficacy, toxicity, and
biological activity. Mayo Clin Proc, 2004, 79:875–882.
Roche-Lestienne C, Lai JL, Darre S, et al. A mutation conferring
resistance to imatinib at the time of diagnosis of chronic
myelogenous leukemia. N Engl J Med, 2003, 348:
2265–2266.
Rosenberg SA. Interleukin-2 and the development of immunotherapy
for the treatment of patients with cancer. Cancer J Sci Am,
2000, 6:S2–S7.
San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus
melphalan and prednisone for initial treatment of multiple
myeloma. N Engl J Med, 2008, 359:906.
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone
or with bevacizumab for non-small-cell lung cancer. N Engl J
Med, 2006, 355:2542–2550.
Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic
events in patients with metastatic carcinoma treated
with chemotherapy and bevacizumab. J Natl Cancer Inst,
2007, 99:1232–1239.
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell,
2000, 103:211–225.
Schwartz RN, Stover L, Dutcher J. Managing toxicities of highdose
interleukin 2. Oncology, 2002, 16:11–20.
Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in
the trastuzumab clinical trials experience. J Clin Oncol, 2002,
20:1215–1221.
Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung
cancer: An evolving story. Annu Rev Med, 2008, 59:
429–442.